We speculate that some transcription factors we predicted contribute to these differentially expressed genes we identified and might be potential adjuvant therapeutic targets for PD1 and PDL1 immune checkpoint blockade therapy in lung adenocarcinoma. The gene discussed is CD274; the disease is lung adenocarcinoma.